Based in Paris, France, Cellectis SA continues to advance its mission within the biotechnology sector, focusing on the development of next-generation cancer therapies. As a specialized biopharmaceutical company, Cellectis is dedicated to the engineering of T-cells to create innovative immunotherapies. Central to their scientific approach is the development of gene-edited CAR-T cells, a technology known as UCART, which aims to redefine the landscape of oncology treatment through precision gene editing.

The company’s strategic focus on engineered T-cell therapies places it at the forefront of the immunotherapy field. By leveraging advanced gene-editing techniques, Cellectis seeks to establish a new standard in how the immune system is harnessed to combat cancer. This specialized focus underscores the company’s commitment to addressing complex medical challenges through high-level biotechnological innovation.

From a market perspective, Cellectis is a publicly traded entity, maintaining listings on both the NYSE and Euronext Paris. Since its Initial Public Offering (IPO) on February 7, 2007, the company has navigated the complexities of the healthcare industry, currently maintaining a market capitalization of 77,640,000 EUR.

Recent market data reflects the volatility often associated with the biotechnology sector. As of the close of trading on November 18, 2026, the company’s share price stood at 0.98 EUR. This figure sits within a significant 52-week trading range, which saw a high of 4.75 EUR in November 2025 and a low of 0.89 EUR in October 2026. Currently, the company reports a price-to-earnings ratio of -0.849, reflecting its ongoing investment in research and development as it pursues its long-term therapeutic goals.